Glivec 400mg tablet

This medicine can make your skin more sensitive to sunlight than usual. Sun exposure may lead to rashes, itching, redness, or even severe sunburn. To protect yourself outdoors, wear suitable clothing and apply sunscreen with an SPF of at least 15. If you notice a burning sensation on your skin, inform your doctor. The human body reacts differently to the Glivec 400mg tablet. Responses or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of the Glivec 400mg tablet are mentioned below:

• Diarrhea
• Vomiting
• Nausea
• Loss of appetite
• Dizziness
• Extreme fatigue 
• Blurred vision
• Irregular heart rate
• Chest pain
• Muscle cramps
• Pink eye 
• Redness and rashes, Swelling of joints
• Trouble sleeping
• Hair loss
• Shortness of breath
• Yellowing of eyes and skin
• Pink mucous in the cough
• Sudden weight loss or weight gain
• Peripheral edema

• Take the dose of the Glivec 400mg tablet as per your healthcare provider’s prescription.
• Do not stop taking the medicine suddenly, unless your doctor tells you.
• This medicine is given under the strict supervision of a doctor. Do not self-administer.
• Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider.
• Glivec 400mg tablet can be taken without food or with food.
• The doctor will provide emergency medical treatment.
• You should not break, crush, or chew the medicine; it should be swallowed as a whole.

1. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P. (2024). Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 44(2):158-62 - https://pubmed.ncbi.nlm.nih.gov/14747424/
2. Zhu J, Yang Y, Zhou L, Jiang M, Hou M. (2024). A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. BMC Cancer. 10:199 - https://pubmed.ncbi.nlm.nih.gov/20465813/
3. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. (2025). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279(5350):577–580 - https://www.scirp.org/reference/referencespapers?referenceid=2656333
4. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. (2024). KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 160(5):1567–1572. - https://pubmed.ncbi.nlm.nih.gov/12000708/
5. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. (2025). Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer. 88(1):66–74. - https://pubmed.ncbi.nlm.nih.gov/10618607/
6. Demetri GD, von Mehren M, Blanke CD, Abbeele AD Van den, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. (2024). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347(7):472–480.